Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN)
On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Stevens Capital Management Matthew Tewksbury | 0 | $0 | 0% | |
| 2. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | $314,468.75 | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | $70,955.37 | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | $930,759.69 | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | $3,503.36 | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | $11,924.48 | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.31 | 1,786 | $105,927.66 | 14,173 | 2025-05-20 | Filing | |
| $64.92 | 273 | $17,723.16 | 32,700 | 2025-05-02 | Filing | |
| $71.52 | 1,295 | $92,618.40 | 16,955 | 2025-03-19 | Filing | |
| $71.28 | 7,034 | $501,355.38 | 87,655 | 2025-03-06 | Filing | |
| $68.38 | 1,344 | $91,902.72 | 13,105 | 2025-02-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,127,847 | $1,077,337,946 | 0.02% | |
| 2. | 2,211,721 | $131,442,578 | 0.02% | |
| 3. | 1,419,067 | $84,335,152 | 0.12% | |
| 4. | 1,283,622 | $76,426,918 | 0.07% | |
| 5. | 766,432 | $45,549,053 | 0.06% |
News See All
15 Large Cap Stocks Under $100 With Huge Upside Potential
The large-cap stock universe comprises mature companies with market capitalizations ranging between $10 billion and $200 billion.
10 Cheap Stocks with Huge Upside Potential
We’re only one month into 2026, and the progress of global economies has been anything but normal.
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best NASDAQ stocks to buy in 2026. On December 22, H.C.
12 Best NASDAQ Stocks to Buy in 2026
On December 30, Victoria Fernandez, Crossmark Chief Market Strategist, joined 'Closing Bell' on CNBC to discuss investment strategies for the technology sector as we head into 2026.
Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the ridiculously cheap stocks to buy now. As of December 26, BioMarin Pharmaceutical Inc.
13 Ridiculously Cheap Stocks to Buy Now
Markets are hardly rational, and that’s what makes things so interesting.
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition
TheFly reported on December 19 that BMRN announced it will acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion, paying $14.50 per share.
7 Most Promising Gene Editing Stocks According to Analysts
Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, delete, or modify DNA within living cells.
BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus
BioMarin Pharmaceutical extended its winning streak to a third straight day on Friday, surging 17.71 percent to finish at $61.15 apiece, as investors took heart from its expansion initiatives following...